HopeStage
Back to all studies
CompletedNCT01140620

Ketamine and Risperidone Effects on Thinking and Memory

About this titleRead the official source — NCT01140620
Medication studyAges 18–45United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
London and 2 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2010
Recruitment status
Completed
Enrollment listed in the registry
87
Sponsor
University of Manchester
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT01140620
Official title
Show the full official title

Effects of NMDA Receptor Antagonism on Cognitive Processes in Healthy Volunteers and Its Reversal by a Dopamine Antagonist: Comparison to Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London · Manchester · Cardiff

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Manchester, a university.

Did this study involve medication?

Yes. The study involved medication, including ketamine, risperidone, saline and placebo risperidone.

Who was this study for?

Listed age limits: 18 years to 45 years.

Want to explore more studies?

Explore studies